Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMG 655 + paclitaxel + carboplatin
- Development stage
- Preclinical
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AMG 655 + paclitaxel + carboplatin is a combination regimen used experimentally in oncology, where **AMG 655 (conatumumab)** is a fully human IgG1 agonist monoclonal antibody that targets **death receptor 5 (DR5)**, activating apoptotic pathways in tumor cells through caspase activation. Paclitaxel is a microtubule stabilizer, inducing cell cycle arrest, and carboplatin is a platinum-based agent that crosslinks DNA and induces apoptosis. AMG 655 amplifies the apoptotic effect of cytotoxic agents like paclitaxel and carboplatin by potentiating death receptor signaling. The combination is designed to enhance antitumor activity, primarily in solid tumors where apoptosis resistance may limit chemotherapy efficacy. Amgen developed AMG 655 as a targeted immunotherapy.
- Brand names
- conatumumab
- Other names
- death receptor 5 agonist antibody + paclitaxel + carboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNATNFRSF10B (DR5)
Beyond the preview
Go deeper on AMG 655 + paclitaxel + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMG 655 + paclitaxel + carboplatin.